Posts about:
Despite the transformative potential of multiomics—integrating proteomics, transcriptomics, epigenomics, and genomics across modalities—realizing its promise is challenging. Scientists have long been forced to cobble together disconnected datasets and tools that are each optimized for a single omic layer. The result? Missed connections, shallow interpretations, and insights that remain just out of reach. But that’s changing.
Illumina Connected Insights, Illumina’s flagship platform for oncology research variant interpretation and reporting, has evolved significantly over the past few years to empower our customers on their precision oncology journey. Illumina’s investment in turnkey oncology informatics solutions is one of many ways in which we continuously commit to enabling research for applications such as MRD, risk stratification, and tumor subtyping. Our latest release of Connected Insights version 5.2 brings that and more, making NGS accessible to a wider range of oncology labs with more accurate, meaningful answers.
In the last few years Illumina DRAGEN secondary analysis has established incredible gains in accuracy and comprehensiveness. Recent peer reviewed publication in Nature Biotechnology showcased how DRAGEN provides a vastly more comprehensive and accurate genome and variant detection than other solutions available today. DRAGEN v4.4 now powers an even more comprehensive and accurate genome with simplicity and ease of use, providing rich capabilities for emerging multiomic applications and clinical research workflows.
Mar 03, 2025 | Episode 87 | 24 mins
Last month, Illumina released Connected Insights v5.1, providing oncology customers with new variant curation capabilities that make using our flagship oncology interpretation platform even easier to use. Building on version 5.0 and earlier releases, the latest iteration of Connected Insights makes clinical research variant interpretation more powerful for a range of oncology use cases such as heme malignancy clinical research.
Hematologic malignancies account for a large number of new cancer cases diagnosed in the United States each year, at around 9.5%. Characterization of genomic mutations at the many different stages of hematopoietic differentiation can help better understand the molecular drivers behind distinct tumor subtypes and disease etiology of blood cancers, unlocking new insights into myeloma, lymphoma, and leukemia-associated genes. In contrast to traditional single-gene methods, targeted and whole genome next-generation sequencing (NGS) offers significant advancements in sensitivity and scale, providing greater visibility into important drivers of hematologic malignancies.
Connected Insights version 5.0 unlocks key new functionality for somatic oncology research applications, including AI algorithms to support variant prioritization and oncogenicity prediction, as well as enriched visualization and curation capabilities. See the latest software release in action by requesting a demo by a technical specialist.
Clarity LIMS 6.3 brings a suite of new features designed to enhance customization, ease of use, and flexibility. In this article, we will explore the following key updates:
Introducing DRAGEN v4.3! This latest version brings a full suite of innovative features enabling unparalleled genomic analysis.